Clinical
B7-H3 radiopharmaceutical enters first-in-human tumor trial
The first patient in the Phase 1/2a study received the investigational B7-H3-targeted radiopharmaceutical therapy at BAMF Health.
Section
Clinical News
Imaging research, modality advances, and clinical practice updates.
Clinical
Urine test may reduce prostate MRI and biopsy use
Vanderbilt Health researchers reported that MyProstateScore 2.0 Active Surveillance outperformed PSA-based testing and MRI for monitoring low-risk prostate cancer.
Clinical
Siemens Healthineers wins ARPA-H funding for Flash therapy
ARPA-H awarded Siemens Healthineers’ Varian business up to $60M over 5 years to advance photon Flash radiotherapy.
Clinical
MRI study links low-level drinking to brain changes
Researchers found that age and lifetime low-level alcohol exposure were associated with lower cortical perfusion and thinner cortex on MRI in healthy adults.
Clinical
Radiotracer access gaps narrow after copper-64 adoption
A JACR study found that gallium-68 PET radiotracer adoption widened rural access gaps for neuroendocrine tumor imaging, while copper-64 DOTATATE later reduced those differences.
Clinical
Radiotracer shows promise for endometriosis imaging
A phase 2 DETECT study found that 99mTc-maraciclatide SPECT/CT imaging was concordant with surgical findings in 16 of 19 participants with suspected or confirmed endometriosis.
Clinical
Radiopharmaceutical shows remission in pancreatic cancer model
Researchers reported that ¹⁷⁷Lu-AKIR001 achieved complete remission in 40% of treated mice with pancreatic ductal adenocarcinoma xenografts.
Clinical
LUMINA trial tests manganese-based MRI contrast alternative
The phase 2/3 trial is evaluating mangaciclanol, GE HealthCare’s investigational manganese-based MRI contrast agent.
Clinical
Routine chest X-ray measure may predict lung surgery outcomes
Researchers found that lower preoperative diaphragmatic dome height on chest X-rays was associated with poorer 3-year survival after lung cancer surgery. The measurement may offer a low-cost way to identify higher-risk patients before lobectomy.
Clinical
Telix phase 3 trial tests radiopharmaceutical therapy for recurrent glioblastoma
The IPAX BrIGHT trial is evaluating TLX101-Tx with lomustine versus lomustine alone in patients with recurrent glioblastoma.
Clinical
Ultrasonic biopsy needle increases tissue yield in pilot study
Researchers found that ultrasound-enhanced fine-needle aspiration biopsy produced larger tissue samples than conventional fine-needle and core-needle biopsy in benign parotid gland tumors without reducing sample quality.
Clinical
Sirtex reports 100% local tumor control in HCC trial
The DOORwaY90 study reported a 90% complete response rate and 99% best overall response rate for SIR-Spheres Y-90 resin microspheres.
Clinical
Telix glioma PET agent moves toward FDA decision
The FDA assigned a September 11, 2026, PDUFA goal date for Pixclara, an investigational F-18 FET PET agent for glioma imaging.
Clinical
Huntsman treats first patients in Ac-225 RYZ401 trial
The Phase 1 first-in-human trial is evaluating RYZ401, an Ac-225-labeled radiopharmaceutical targeting somatostatin receptors in neuroendocrine tumors and other solid tumors.